⌘K
Credent Connect SME IPO is a company operating in the healthcare ecosystem and logistics platform sector. The company aims to leverage its established client relationships and widespread domestic reach to expand its services and invest in technological capabilities. The IPO is a Book Build Issue on the NSE SME platform.
Deterministic verdict 'Avoid': listing=74/Neutral, short=54/Neutral, long=57/Neutral; overall=56.6; confidence=91.2/100 | computed financials: fin=67, growth=30, D/E=0.5 (70% math / 30% model) | market signals: alignment=n/a (OFS None%), anchor quality=55 (marquee 22.6%), GMP trend=fading, overhang=80 (-4.0 pts short-term) | demand profile: reservation weights QIB/NII/Ret 29%/21%/50%, QIB effective demand=37.32x, institutional contribution=24%, breadth=0.97 | unlocks: anchor unlock ~14.2% of issue at T+30d, ~14.2% at T+90d | red flags: R2_persistent_losses (declining/negative profit trajectory (CAGR -15.4%)); R5_litigation (litigation disclosed (advisory, not a specific severe matter)); R10_data_conflict (conflicting source data: roe_pct (investorgain=61.81 vs drhp_computed=14.2)) | rule: declining/negative profit trajectory (CAGR -15.4%); governance concern (governance_score 3 <= 3; Neutral ceiling). | Analyst notes: The IPO receives an 'Apply' verdict with moderate confidence. This is driven by strong market sentiment (high subscription, decent GMP), attractive post-IPO P/E, and impressive recent return ratios and margins. However, the verdict is tempered by significant governance risks due to ongoing litigations, historical inconsistencies in financial growth, and concerns regarding cash flow and working capital. The balance of strong market demand and attractive valuation against notable risks leads to a cautious 'Apply'.
Listing-day performance is not available yet. It will appear here once this IPO has listed and results are recorded.
| Category | Shares Offered | % of Issue | Share |
|---|---|---|---|
| QIB | 23,52,000 | 47.34% | |
| NII (HNI) | 7,08,000 | 14.25% | |
| Retail | 16,56,000 | 33.33% | |
| Market Maker | 2,52,000 | 5.07% |
| Investor | |||
|---|---|---|---|
| ABAKKUS VENTURE OPPORTUNITIES FUND | 2,64,600 | ₹5 Cr | 18.85% |
| MOTILAL OSWAL FINVEST LTD. | 2,11,800 | ₹4 Cr | 15.09% |
| 360 ONE LVF TREASURY SOLUTIONS FUND | 53,400 | ₹1.01 Cr | 3.8% |
| HEM GROWTH OPPORTUNITIES FUND | 2,37,000 | ₹4.48 Cr | 16.88% |
| MINT FOCUSED GROWTH FUND PCC-CELL 1 | 2,64,600 | ₹5 Cr | 18.85% |
| LRSD SECURITIES PVT.LTD. | 53,400 | ₹1.01 Cr | 3.8% |
| FINAVENUE CAPITAL TRUST-FINAVENUE GROWTH FUND | 53,400 | ₹1.01 Cr | 3.8% |
| MERU INVESTMENT FUND PCC-CELL 1 | 1,59,000 | ₹3.01 Cr | 11.32% |
| RELIGO COMMODITIES VENTURES TRUST-RELIGO COMMODITIES VENTURE FUND | 53,400 | ₹1.01 Cr | 3.8% |
| SHINE STAR BUILD-CAP PVT.LTD. | 53,400 | ₹1.01 Cr | 3.8% |
Premium gain of 29.1% over issue price.
Strong return ratios (ROE 61.81%, ROCE 40.0%) as of Mar 31, 2026.
Improving EBITDA and PAT margins as of Mar 31, 2026.
Healthy post-IPO promoter holding (63.75%).
Very strong overall IPO subscription across all categories.
Operating in a growing industry with a 10.5% CAGR.
Attractive Post-IPO P/E of 18.68x.
Comprehensive Healthcare Ecosystem and Logistics Platform.
Well established relationships with clients and widespread domestic reach.
Successful expansion into new geographies, deeper client engagement, effective leverage of technology, and resolution of legal issues.
Consistent industry growth, stable client relationships, and gradual improvement in operational efficiency.
Intensified competition, failure to renew key client contracts, adverse outcomes from ongoing litigations, or continued negative cash flows.
Strong market sentiment indicated by high subscription rates across all categories and a decent GMP suggests a good probability of listing gains.
While listing gains are likely, short-term performance beyond listing might be volatile due to underlying risks like litigation and cash flow concerns, despite attractive valuation and strong recent margins.
Long-term prospects are clouded by significant governance risks (litigation) and historical inconsistencies in profit growth and cash flows. While the industry has growth potential and recent margins are strong, these risks need to be mitigated for sustained long-term value creation.
Final verdict: Avoid (confidence High).
Positive: Strong ROE (61.81%) and ROCE (40.0%) as of Mar 31, 2026.
Red flag: declining/negative profit trajectory (CAGR -15.4%)
Advisory: litigation disclosed (advisory, not a specific severe matter)
Listing-gain vs long-term: Neutral / Neutral.